Read the Latest News

Metal Implants and Dental Amalgam: The FDA Announces Public Meeting and Paper

The U.S. Food and Drug Administration (FDA) announced a paper on metal-containing implants and a panel meeting as part of ongoing efforts to evaluate materials in medical devices to address potential safety questions.

Drug Induced Bruxism

The authors of this article state that orofacial movement disorders (bruxism) are treated typically by dental professionals and not by those specialists (neurologists) researching and treating the other movement disorders (Parkinson's disease, Huntington's disease, tremors, etc.). Again, this is more evidence of the complexity of TMD and the need for multidisciplinary research and treatment in TMD.

Cervical Muscle Tenderness in Temporomandibular Disorders and Its Associations with Diagnosis, Disease-Related Outcomes, and Comorbid Pain Conditions

To analyze cervical tenderness scores (CTS) in patients with various temporomandibular disorders (TMD) and in controls and to examine associations of CTS with demographic and clinical parameters.

You, Your Esophagus and TMD

The esophagus is a roughly ten-inch hollow tube that descends from your throat through the diaphragm into the stomach. Normally, it is a one-way street transporting food you swallow to the stomach for digestion. But in GERD— Gastroesophageal Reflux Disease— the flow can reverse so that stomach contents (including gastric acids) are regurgitated upwards to cause a burning sensation (heartburn), nausea, pain and other distressing symptoms.

It's Time to Be Part of the Solution

The National Academy of Medicine (NAM) Study on Temporomandibular Disorders (TMD) is well underway. We strongly encourage everyone affected by TMD to write to the NAM committee letting them know what it is like to live with TMD and your experiences with getting care.

NIH GRANT OPPORTUNITIES

  • Oct 11, 2019

In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments. The TMJ Association promotes and encourages basic and clinical research on TMD.  We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.

The Intersection of Sex and Gender Influences on Health and Disease (R01)

https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-029.html

  • Posted Date: September 27, 2019
  • Open Date: October 25, 2019
  • Expires: November 27, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including:  (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women’s Health (ORWH) and the scientific partnering Institutes and Centers across NIH.

 

Achieving Tissue Robustness Through Harnessing Immune Systems Plasticity

(R21 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-19-173.html

(R01) Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-19-172.html

  • Posted Date: January 29, 2019
  • Open Date: May 16, 2019
  • Expires: May 8, 2022

This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.

Recent advances in understanding diseases and conditions involving DOC tissues – periodontitis, peri-implantitis, temporomandibular joint disorders (TMD), oral and oropharyngeal cancers, Sjögren’s Syndrome, and HIV/AIDS with its associated oral opportunistic infections, among others - demonstrate that the immune system significantly contributes to disease onset, progression, and persistence.

HEAL Initiative Funding Opportunities

HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/rfa-eb-18-003.html

The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-19-016.html

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-19-017.html

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-19-018.html

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants.  The clinical trial should provide data to answer key questions about the function or final design of a device and is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Anatomical and Functional Mapping of Pain-Related Visceral Organ Neural Circuitry (U01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/rfa-rm-19-001.html

The purpose of this NIH Funding Opportunity Announcement (FOA) is to invite research applications proposing to map neural circuitry mediating visceral organ pain. This FOA is part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Common Fund program and is coordinated with the Translational Devices to Treat Pain (TDTP) initiatives of the NIH HEAL program (see Companion Funding Opportunities above). Detailed mapping of pain-mediating circuitry originating from visceral organ afferents will leverage the SPARC program to produce maps that could accelerate the development of non-addictive approaches to treat pain.

Additional information about the HEAL Initiative can be found at: NIH Director’s Statement regarding new HEAL FOAs and Updated NIH HEAL Research Plan

  • Posted Date: December 10, 2018
  • Open Date: varies see specific funding opportunity
  • Expires: February 23, 2021

Global Brain and Nervous System Disorders Research Across the Lifespan

  • Posted Date: June 19, 2018
  • Open Date: October 7, 2018
  • Expires: October 7, 2020
The mission of the National Institute of Dental and Craniofacial Research (NIDCR) is to improve dental, oral, and craniofacial health through research, research training, and the dissemination of health information; for further details, please see the NIDCR Strategic Plan 2014-2019 (https://www.nidcr.nih.gov/research/ResearchPriorities/StrategicPlan/). Through this FOA, NIDCR encourages research in orofacial pain, trigeminal neuralgia, temporomandibular joint disorder, and oral cancer pain.

 

Research on Chronic Overlapping Pain Conditions

  • Posted Date: September 26, 2018
  • Open Date: January 16, 2019
  • Expires: January 8, 2022

The purpose of this FOA is to encourage epidemiological, clinical and translational research that will increase our understanding of the presence of multiple chronic pain conditions in subjects with pain. Recent findings suggest substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, their underlying etiologies, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with research interests bridging expertise in pain mechanisms and translational and clinical expertise to address important unresolved questions about overlapping pain conditions.

Chronic pain affects approximately 100 million Americans and exacts large economic, social and personal costs. It is a major public health challenge that needs to be addressed at multiple levels including the generation of new scientific knowledge that will enhance our understanding of these conditions. Current research efforts in chronic pain conditions have focused on single disorders or types of pain such as neuropathic and inflammatory pain. These research efforts have generated a substantial body of information advancing our discovery and understanding of the underlying mechanisms of pain onset and development, the transition from acute to chronic pain, and promising therapeutic targets for treating acute and chronic pain. Over the past twenty years sporadic reports have documented the presence of more than one chronic pain condition in subjects with pain. Studies have identified overlap between a number of chronic pain conditions, including temporomandibular joint disorder (TMD), fibromyalgia (FM), vulvodynia, functional gastrointestinal disorders such as irritable bowel syndrome (IBS), migraine, and urologic chronic pelvic pain syndromes (UCPPS). These results suggest that chronic pain conditions may not be localized conditions, but may share symptoms and mechanisms that involve a general central nervous system dysfunction as well as disorder-specific symptoms. More recent evidence is supportive of the idea that chronic pain conditions are complex disorders consistent with a biopsychosocial model of pain, and exhibit substantial overlap. Therefore, this may be an opportune time to encourage research efforts that focus, not on single pain conditions, but on subjects with multiple chronic pain disorders.

Analytical and/or Clinical Validation of a Candidate Biomarker for Pain

(R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-046.html 

  • Posted Date: September 19, 2018
  • Open Date: October 27, 2018
  • Expires: March 13, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice. 

Discover and Validation of Novel Targets for Safe and Effective Pain Treatment

(R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-043.html 

(R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-042.html 

  • Posted Date: September 19, 2018
  • Open Date: October 27, 2018
  • Expires: November 13, 2019

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics.  Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.

This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

Discovery of Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)

(R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-041.html

  • Posted Date: August 2, 2018
  • Open Date: October 27, 2018
  • Expires: March 13, 2020

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation research using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.

Clinical Validation of Candidate Biomarkers for Neurological Diseases

  • Posted Date: February 14, 2018
  • Open Date: March 17, 2018
  • Expires: February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond).
 

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System

(UH2/UH3): https://grants.nih.gov/grants/guide/pa-files/PAR-17-205.html

  • Posted Date: December 21, 2017
  • Open Date: January 7, 2018
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions.  Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.     - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html#sthash.mGoDkIgW.dpuf
The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches. - See more at: http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html#sthash.viviyVB9.dpuf

Family-Centered Self-Management of Chronic Conditions

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-380.html

(R01):https://grants.nih.gov/grants/guide/pa-files/PA-18-383.html

  • Posted Date: November 21, 2017
  • Open Date: January 16, 2018 / January 5, 2018
  • Expires: January 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-386.html

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-389.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: January 8, 2021

The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. 

The Biomarkers Consortium

The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.

The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.

Information about the Foundation for NIH is available at http://www.fnih.org.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System

  • Posted Date: December 21, 2017
  • Open Date: January 7, 2018
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. 

NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions.  Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

Mechanisms Underlying the Contribution of Sleep Disturbances to Pain

(R01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PA-19-200.html?utm_medium=email&utm_source=govdelivery

(R21 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PA-19-201.html?utm_medium=email&utm_source=govdelivery

  • Posted Date: February 28, 2019
  • Open Date: May 16, 2019
  • Expires: May 8, 2022

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf

In Treating TMJ

To view or order a free booklet about TMJ Disorders, visit the National Institutes of Health website.

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
National Institutes of Health
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health